Investment Rating - The investment rating for the company is "Accumulate" with a target price of 16.84 CNY [6][13]. Core Viewpoints - The company is experiencing significant improvement in operations, particularly in the adult incontinence products segment, driven by population aging and product innovation [2][13]. - The company has adjusted its profit expectations for 2025-2027, forecasting EPS of 0.14 CNY for 2025, 0.14 CNY for 2026, and 0.15 CNY for 2027, reflecting a robust growth trajectory in its proprietary brand business [13][14]. - The company has actively participated in the formulation of industry standards, completing 20 research projects and contributing to four national and group standards [13]. Financial Summary - Total revenue for 2025 is projected at 1.136 billion CNY, with a year-on-year growth of 5.3% [4]. - The net profit attributable to the parent company is expected to reach 38 million CNY in 2025, reflecting a growth of 20.5% [4]. - The gross profit margin for Q2 2025 is reported at 23.62%, with a net profit margin of 3.60% [13]. Product Performance - In the first half of 2025, revenue from adult incontinence products was 287 million CNY, up 4.62% year-on-year, while revenue from baby care products was 209 million CNY, up 5.60% [13]. - The company has seen a significant increase in net profit for Q2 2025, with a year-on-year growth of 98.42% [13]. Market Position - The company has a total market capitalization of 3.763 billion CNY and a current price range of 6.91 to 16.98 CNY over the past 52 weeks [7][8]. - The company maintains a strong balance sheet with a net asset return rate of 2.7% projected for 2025 [4][14].
可靠股份（301009）：深耕银发经济，25Q2经营显著改善